CN105963677A - 一种眼部护理凝胶及其制备方法 - Google Patents
一种眼部护理凝胶及其制备方法 Download PDFInfo
- Publication number
- CN105963677A CN105963677A CN201610285875.XA CN201610285875A CN105963677A CN 105963677 A CN105963677 A CN 105963677A CN 201610285875 A CN201610285875 A CN 201610285875A CN 105963677 A CN105963677 A CN 105963677A
- Authority
- CN
- China
- Prior art keywords
- eye
- gel
- vitamin
- parts
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种眼部护理凝胶及其制备方法,所述眼部护理凝胶主要是由以下重量份的成分组成:羟丙基甲基纤维素3‑10份、瓜尔豆胶1‑4份、奈多罗米钠0.1‑0.3份、倍他洛尔0.1‑0.5份、吡罗昔康0.2‑0.6份、硫酸酯0.1‑0.3份、甘草酸二钾0.1‑0.2份、杆菌肽0.05‑0.15份、酒石酸肾上腺素0.8‑1.2份、牛磺酸1.5‑3份、原花青素0.3‑1份、维生素A 0.4‑1份、维生素B12 0.4‑1份、防腐剂0.01‑0.03份、缓冲剂2‑5份、等渗剂2‑8份、凝胶基质70‑120份。以上所有成分共同配合,加速受损的眼部组织恢复,防止感染性并发症,缓解眼部不适,对眼部起到很好的护理作用。能够有效缓解眼疲劳、消除黑眼圈、眼周水肿,并抗皱、舒活,对预防近视,恢复视力健康,控制预防眼疾病症等也有一定的效果。
Description
技术领域
本发明涉及眼部护理技术领域,具体是涉及一种眼部护理凝胶及其制备方法。
背景技术
随着现代文化生活节奏的加快,工作、学习过度紧张,心理素质负担过重,加之生态环境的不洁污染、如空气尘埃、烟雾等空气质量的影响及自身精神紧张,劳逸协调不当,长期用眼过度、熬夜,眼睛得不到充分的调养和休息,同时诸多因素诱发的眼睛病变越来越多,不同程度的病变可致眼视力下降,形成近视、弱视、视疲劳或出现眼部酸困、眼框疼痛等症。最常见的就是黑眼圈和眼周水肿。经过现代科学研究证明,熬夜后出现的黑眼圈和眼周水肿主要是由于眼周微循环障碍引起局部水液滞留和黑色素沉积所形成的结果,对眼部健康和人的外观都会带来不利因素。
长期黑眼圈和眼周水肿是眼疲劳的表现,它往往伴随着眼干、眼涩、眼酸胀,视物模糊甚至视力下降直接影响着人的工作与生活。常见的防止眼疲劳的滴眼液有珍珠明目液、萘敏维滴眼液、牛磺酸等,虽然对缓解眼疲劳有一定的作用,但是长期使用容易产生药物依赖,易于引发局部或全身生理毒性反应等问题,疗效也会越来越不明显,更严重的会导致眼睛的器质性变化,产生严重的后果。
因此,研制一种有效缓解眼疲劳、消除黑眼圈、眼周水肿,并抗皱、舒活的药物是很有必要的。这对消除视疲劳,预防近视,恢复视力健康,控制预防眼疾病症等也有一定的效果。
发明内容
本发明解决的技术问题是提供一种有效缓解眼疲劳、消除黑眼圈、眼周水肿,并抗皱、舒活的眼部护理凝胶及其制备方法。
本发明的技术方案是:一种眼部护理凝胶,主要是由以下重量份的成分组成:羟丙基甲基纤维素3-10份、瓜尔豆胶1-4份、奈多罗米钠0.1-0.3份、倍他洛尔0.1-0.5份、吡罗昔康0.2-0.6份、硫酸酯0.1-0.3份、甘草酸二钾0.1-0.2份、杆菌肽0.05-0.15份、酒石酸肾上腺素0.8-1.2份、牛磺酸1.5-3份、原花青素0.3-1份、维生素A 0.4-1份、维生素B12 0.4-1份、防腐剂0.01-0.03份、缓冲剂2-5份、等渗剂2-8份、凝胶基质70-120份。
进一步地,所述防腐剂为对羟基苯甲酸酯。
进一步地,所述缓冲剂为硼酸。
进一步地,所述等渗剂为氯化钠。
进一步地,所述凝胶基质为水性凝胶,优选泊洛沙姆或透明质酸。
一种眼部护理凝胶,其制备方法为:
(1)精密称取配方量的羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、原花青素、维生素A、维生素B12、防腐剂、缓冲剂、等渗剂、凝胶基质,待用;
(2)将羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、混合,加入相对于混合物总重量55-60倍的注射用水,过滤,滤液待用;
(3)滤液中加入凝胶基质,高压均质处理;向均质处理后的液体中依次加入原花青素、维生素A、维生素B12、防腐剂、缓冲剂,分散处理后,再进行超滤,得到超滤液待用;
(4)超滤液中加入等渗剂,补全注射用水至溶液的浓度为0.3%~0.45%;用pH调节剂调节药液的pH至5~6,所述pH调节剂为磷酸二氢钠;热压蒸汽灭菌30分钟,灌装,即得成品。
本发明的有益效果是:本发明能够有效缓解眼疲劳、消除黑眼圈、眼周水肿,并抗皱、舒活,对预防近视,恢复视力健康,控制预防眼疾病症等也有一定的效果。
其中,倍他洛尔具有减少睫状体眼房水的产生、降低眼内压的作用。牛磺酸能明显促进神经系统的生长发育和细胞增殖、分化,具有调节晶体渗透压和抗氧化等重要作用,可抑制白内障的发生发展。吡罗昔康有明显的镇痛、抗炎、解热及一定的消肿作用。甘草酸二钾具有抑菌、消炎、解毒、抗敏、除臭等多种功效。瓜尔豆胶粘度高,水溶性好,特别适用于配制外用凝胶剂。杆菌肽对革兰阳性细菌和阴性球菌、肺炎双球菌、葡萄球菌、淋球菌、脑膜炎双球菌及螺旋体等均有杀菌作用。酒石酸肾上腺素、奈多罗米钠与其他药物共同作用可以预防过敏。原花青素具有极强的抗氧化、消除自由基的作用,可以强化毛细血管、动脉与静脉血管,因此,它有消肿化淤的功效,毛细血管的阻力减少和渗透性改善,使细胞更容易吸收养分与排除废物。维生素A能够维持正常的视觉功能,是眼睛不可或缺的一种维生素。维生素B12是神经系统功能健全不可缺少的维生素,缺乏维生素B12会导致眼睛及皮肤发黄,皮肤出现局部红肿并伴随蜕皮。以上所有成分共同配合,加速受损的眼部组织恢复,防止感染性并发症,缓解眼部不适,对眼部起到很好的护理作用。
具体实施方式
实施例1:
一种眼部护理凝胶,主要是由以下重量份的成分组成:羟丙基甲基纤维素3份、瓜尔豆胶1份、奈多罗米钠0.1份、倍他洛尔0.1份、吡罗昔康0.2份、硫酸酯0.1份、甘草酸二钾0.1份、杆菌肽0.05份、酒石酸肾上腺素0.8份、牛磺酸1.5份、原花青素0.3份、维生素A 0.4份、维生素B12 0.4份、对羟基苯甲酸酯0.01份、硼酸2份、氯化钠2份、泊洛沙姆70份。
其制备方法为:
(1)精密称取配方量的羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、原花青素、维生素A、维生素B12、防腐剂、缓冲剂、等渗剂、凝胶基质,待用;
(2)将羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、混合,加入相对于混合物总重量55倍的注射用水,过滤,滤液待用;
(3)滤液中加入凝胶基质,高压均质处理;向均质处理后的液体中依次加入原花青素、维生素A、维生素B12、防腐剂、缓冲剂,分散处理后,再进行超滤,得到超滤液待用;
(4)超滤液中加入等渗剂,补全注射用水至溶液的浓度为0.3%;用pH调节剂调节药液的pH至5,所述pH调节剂为磷酸二氢钠;热压蒸汽灭菌30分钟,灌装,即得成品。
实施例2:
一种眼部护理凝胶,主要是由以下重量份的成分组成:羟丙基甲基纤维素6.5份、瓜尔豆胶2.5份、奈多罗米钠0.2份、倍他洛尔0.35份、吡罗昔康0.4份、硫酸酯0.2份、甘草酸二钾0.15份、杆菌肽0.1份、酒石酸肾上腺素1.0份、牛磺酸2.25份、原花青素0.65份、维生素A 0.7份、维生素B120.7份、对羟基苯甲酸酯0.02份、硼酸3.5份、氯化钠5份、透明质酸95份。
其制备方法为:
(1)精密称取配方量的羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、原花青素、维生素A、维生素B12、防腐剂、缓冲剂、等渗剂、凝胶基质,待用;
(2)将羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、混合,加入相对于混合物总重量57.5倍的注射用水,过滤,滤液待用;
(3)滤液中加入凝胶基质,高压均质处理;向均质处理后的液体中依次加入原花青素、维生素A、维生素B12、防腐剂、缓冲剂,分散处理后,再进行超滤,得到超滤液待用;
(4)超滤液中加入等渗剂,补全注射用水至溶液的浓度为0.375%;用pH调节剂调节药液的pH至5.5,所述pH调节剂为磷酸二氢钠;热压蒸汽灭菌30分钟,灌装,即得成品。
实施例3:
一种眼部护理凝胶,主要是由以下重量份的成分组成:羟丙基甲基纤维素10份、瓜尔豆胶4份、奈多罗米钠0.3份、倍他洛尔0.5份、吡罗昔康0.6份、硫酸酯0.3份、甘草酸二钾0.2份、杆菌肽0.15份、酒石酸肾上腺素1.2份、牛磺酸3份、原花青素1份、维生素A 1份、维生素B12 1份、对羟基苯甲酸酯0.03份、硼酸5份、氯化钠8份、泊洛沙姆120份。
其制备方法为:
(1)精密称取配方量的羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、原花青素、维生素A、维生素B12、防腐剂、缓冲剂、等渗剂、凝胶基质,待用;
(2)将羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、混合,加入相对于混合物总重量60倍的注射用水,过滤,滤液待用;
(3)滤液中加入凝胶基质,高压均质处理;向均质处理后的液体中依次加入原花青素、维生素A、维生素B12、防腐剂、缓冲剂,分散处理后,再进行超滤,得到超滤液待用;
(4)超滤液中加入等渗剂,补全注射用水至溶液的浓度为0.45%;用pH调节剂调节药液的pH至6,所述pH调节剂为磷酸二氢钠;热压蒸汽灭菌30分钟,灌装,即得成品。
效果验证:
抗眼袋的临床试验
1、选择对象:选取年龄在22-50岁之间,有长期的眼袋问题,一个月内未进行其他治疗的200名的志愿者,随机分为4组,分别为1组、2组、3组、对照组。
2、治疗方法:1组、2组、3组分别采用实施例1、实施例2、实施例3制备的药物,对照组使用芸蓉集眼部臻悦精华霜,每天涂抹两次,持续30天。对使用前,使用后15天和30天分别进行眼袋和黑眼圈变化记录。
3、疗效判定标准:
显效:眼袋体积减少50%以上或黑眼圈明显淡化;
有效:眼袋体积减少30-50%或黑眼圈减小;
好转:眼袋体积减少10-30%或黑眼圈有所变小;
无效:眼袋体积没有变化或增大或黑眼圈无变化或加重。
治疗结果:
使用15天后,1组、2组、3组祛除眼袋效果:
组别 | 显效 | 有效 | 好转 | 无效 | 总有效率 |
1组 | 12 | 15 | 20 | 3 | 94 |
2组 | 13 | 14 | 22 | 1 | 98 |
3组 | 11 | 16 | 21 | 2 | 96 |
对照组 | 2 | 8 | 27 | 13 | 74 |
使用30天后,1组、2组、3组祛除眼袋效果:
组别 | 显效 | 有效 | 好转 | 无效 | 总有效率 |
1组 | 31 | 10 | 9 | 0 | 100 |
2组 | 26 | 14 | 22 | 1 | 98 |
3组 | 34 | 16 | 21 | 1 | 98 |
对照组 | 6 | 10 | 25 | 9 | 82 |
从以上结果可见,本发明的眼部护理凝胶有效率更高,效果更好。
以上述依据本发明的理想实施例为启示,通过上述的说明内容,相关工作人员完全可以在不偏离本项发明技术思想的范围内,进行多样的变更以及修改。本项发明的技术性范围并不局限于说明书上的内容,必须要根据权利要求范围来确定其技术性范围。
Claims (6)
1.一种眼部护理凝胶,其特征在于,主要是由以下重量份的成分组成:羟丙基甲基纤维素3-10份、瓜尔豆胶1-4份、奈多罗米钠0.1-0.3份、倍他洛尔0.1-0.5份、吡罗昔康0.2-0.6份、硫酸酯0.1-0.3份、甘草酸二钾0.1-0.2份、杆菌肽0.05-0.15份、酒石酸肾上腺素0.8-1.2份、牛磺酸1.5-3份、原花青素0.3-1份、维生素A 0.4-1份、维生素B12 0.4-1份、防腐剂0.01-0.03份、缓冲剂2-5份、等渗剂2-8份、凝胶基质70-120份。
2.如权利要求1所述的一种眼部护理凝胶,其特征在于,所述防腐剂为对羟基苯甲酸酯。
3.如权利要求1所述的一种眼部护理凝胶,其特征在于,所述缓冲剂为硼酸。
4.如权利要求1所述的一种眼部护理凝胶,其特征在于,所述等渗剂为氯化钠。
5.如权利要求1所述的一种眼部护理凝胶,其特征在于,所述凝胶基质为水性凝胶,优选泊洛沙姆或透明质酸。
6.如权利要求1-5所述的一种眼部护理凝胶,其特征在于,制备方法为:
(1)精密称取配方量的羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、原花青素、维生素A、维生素B12、防腐剂、缓冲剂、等渗剂、凝胶基质,待用;
(2)将羟丙基甲基纤维素、瓜尔豆胶、奈多罗米钠、倍他洛尔、吡罗昔康、硫酸酯、甘草酸二钾、杆菌肽、酒石酸肾上腺素、牛磺酸、混合,加入相对于混合物总重量55-60倍的注射用水,过滤,滤液待用;
(3)滤液中加入凝胶基质,高压均质处理;向均质处理后的液体中依次加入原花青素、维生素A、维生素B12、防腐剂、缓冲剂,分散处理后,再进行超滤,得到超滤液待用;
(4)超滤液中加入等渗剂,补全注射用水至溶液的浓度为0.3%~0.45%;用pH调节剂调节药液的pH至5~6;热压蒸汽灭菌30分钟,灌装,即得成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610285875.XA CN105963677A (zh) | 2016-05-03 | 2016-05-03 | 一种眼部护理凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610285875.XA CN105963677A (zh) | 2016-05-03 | 2016-05-03 | 一种眼部护理凝胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105963677A true CN105963677A (zh) | 2016-09-28 |
Family
ID=56994585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610285875.XA Pending CN105963677A (zh) | 2016-05-03 | 2016-05-03 | 一种眼部护理凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105963677A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111097036A (zh) * | 2019-05-05 | 2020-05-05 | 刘祝成 | 眼部护理组合物、产品及其使用方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1698578A (zh) * | 2004-05-17 | 2005-11-23 | 孙凤楼 | 眼贴配方及其制配工艺 |
CN1704077A (zh) * | 2004-05-25 | 2005-12-07 | 谭邦勇 | 一种快速治疗眼球充血病症的中西复方滴眼液 |
CN101073562A (zh) * | 2007-06-22 | 2007-11-21 | 肖正连 | 一种牛磺酸眼用即型凝胶 |
CN101185650A (zh) * | 2006-11-27 | 2008-05-28 | 中国医学科学院医药生物技术研究所 | 喷昔洛韦眼用温度敏感原位凝胶制剂及其制备方法 |
CN101332173A (zh) * | 2007-06-29 | 2008-12-31 | 肖正连 | 一种盐酸倍他洛尔眼用即型凝胶 |
CN101347443A (zh) * | 2007-07-20 | 2009-01-21 | 肖正连 | 一种维生素b12眼用即型凝胶 |
CN102596097A (zh) * | 2009-06-03 | 2012-07-18 | 弗赛特实验室有限责任公司 | 前段药物输送 |
-
2016
- 2016-05-03 CN CN201610285875.XA patent/CN105963677A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1698578A (zh) * | 2004-05-17 | 2005-11-23 | 孙凤楼 | 眼贴配方及其制配工艺 |
CN1704077A (zh) * | 2004-05-25 | 2005-12-07 | 谭邦勇 | 一种快速治疗眼球充血病症的中西复方滴眼液 |
CN101185650A (zh) * | 2006-11-27 | 2008-05-28 | 中国医学科学院医药生物技术研究所 | 喷昔洛韦眼用温度敏感原位凝胶制剂及其制备方法 |
CN101073562A (zh) * | 2007-06-22 | 2007-11-21 | 肖正连 | 一种牛磺酸眼用即型凝胶 |
CN101332173A (zh) * | 2007-06-29 | 2008-12-31 | 肖正连 | 一种盐酸倍他洛尔眼用即型凝胶 |
CN101347443A (zh) * | 2007-07-20 | 2009-01-21 | 肖正连 | 一种维生素b12眼用即型凝胶 |
CN102596097A (zh) * | 2009-06-03 | 2012-07-18 | 弗赛特实验室有限责任公司 | 前段药物输送 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111097036A (zh) * | 2019-05-05 | 2020-05-05 | 刘祝成 | 眼部护理组合物、产品及其使用方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109091675B (zh) | 一种复方低浓度阿托品类药物滴眼液及其制备方法 | |
CN107802561A (zh) | 一种护理眼部凝胶及其生产方法 | |
EP0648114A1 (de) | Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels. | |
CN101317847A (zh) | 一种眼用或耳鼻用药物组合物及其用途 | |
CN111991415A (zh) | 一种眼部护理组合物及其制备方法和用途 | |
CN109675038A (zh) | 增强低浓度阿托品类药物安全性和临床疗效的组合物 | |
CN109419770A (zh) | 一种间充质干细胞外泌体滴眼液及其制备方法和应用 | |
CN101278908B (zh) | 一种左氧氟沙星滴眼液 | |
CN104824510A (zh) | 具有视力保护作用的保健食品 | |
CN105963677A (zh) | 一种眼部护理凝胶及其制备方法 | |
CN103432069A (zh) | 不含抑菌剂的氧氟沙星滴眼液及其制备方法 | |
CN102670493A (zh) | 盐酸洛美沙星滴眼液及其制备方法与应用 | |
CN108721329B (zh) | 一种用于缓解鼻炎的护理液及其制备方法 | |
CN106963770A (zh) | 一种用于预防和治疗干燥性角/结膜炎的滴眼液及其制备方法和用途 | |
CN103417525B (zh) | 葡萄糖酸锌片、六合维生素丸在治疗眼屈光不正中的应用 | |
Yarmamedov et al. | Study of the pharmacological impact of polymeric membranes with antibacterial effect in traumatic lesions of cornea | |
CN102008488A (zh) | 一种曲安奈德眼用制剂及其制备方法 | |
CN108066401A (zh) | 一种用于治疗鼻炎的药物 | |
CN105168237A (zh) | 一种复方凝胶保湿润眼液 | |
CN1985801A (zh) | 苄达赖氨酸滴眼液及其制备方法 | |
CN114146075A (zh) | 一种治疗近视的牛磺酸外用药及其制备方法与应用 | |
CN105902686A (zh) | 一种含有纳米碳晶的原位凝胶眼药水及其制备方法 | |
CN100384435C (zh) | 一种治疗鼻腔疾病的盐水药液及应用装置 | |
CN104622800A (zh) | 苄达赖氨酸滴眼液及制备方法 | |
CN111110817A (zh) | 一种治疗眼疾的中药组合物、制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160928 |
|
RJ01 | Rejection of invention patent application after publication |